Recurrent High Grade Gliomas
Conditions
Brief summary
Brain imaging tests are routinely used to detect the presence of a brain tumor or to evaluate the response to treatment. Sometimes the images obtained are not specific and the only way to establish a diagnosis is by obtaining a tissue sample. The hypotheses of the study is to determine if multimodal MR technique will provide tissue signatures that differentiate between tumor progression and treatment related necrosis in high grade glioma patients.
Interventions
DEVICE3T MRI
The introduction of the 3T scanners provides a potential opportunity to improve the quality of imaging in neuro-oncology.
Sponsors
Dartmouth-Hitchcock Medical Center
Study design
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically proven high grae glioma with central pathology review at DHMC * Age 18 equal to or greater than 18 years * Karnofsky performance greater or equal to 60% * Patients must have received radiation therapy and chemotherapy but should not have received any anti-angiogenesis therapy.
Exclusion criteria
* Any patient who requires urgent surgical resection of MRI abnormality would not be eligible * Pregnant women are not eligible
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To prospectively acquire multiparameter MR variables at 1.5T and 3T MRI from treated high grade glioma patients to assign tissue signatures for tumor recurrence and radiation necrosis as established by pathologic examination. | 24 months |
Secondary
| Measure | Time frame |
|---|---|
| To compare the predictive values of the multiparameter MR tissue signatures acquired at 1.5T and 3T | 24 months |
Countries
United States
Outcome results
None listed